EANS-News: AGENNIX AG / Agennix AG Announces Changes to Management Board and Supervisory Board

--------------------------------------------------------------------------------
Corporate news transmitted by euro adhoc. The issuer/originator is solely
responsible for the content of this announcement.
--------------------------------------------------------------------------------

Board of Directors (Appointments and Changes)

Heidelberg (euro adhoc) - Planegg/Munich (Germany), Princeton, NJ and
Houston, TX, March 4, 2011 - Agennix AG (Frankfurt Stock Exchange:
AGX) today announced changes to its Management Board and Supervisory
Board.

Friedrich von Bohlen und Halbach´s term as interim Chief Executive
Officer expired on February 28, 2011. Effective March 1, 2011, as
resolved by the Supervisory Board, the Company is being led by a
two-person Management Board comprised of Dr. Torsten Hombeck, Chief
Financial Officer, and Dr. Rajesh Malik, Chief Medical Officer. Dr.
Hombeck also has been appointed to serve as spokesperson of the
Management Board.

Dr. Hombeck said, "On behalf of all of us at Agennix, I would like to
warmly thank Dr. von Bohlen for serving as CEO during the formation
and integration of the Company. His leadership and experience during
this critical time have been very helpful."

The Company also reported changes to its Supervisory Board. Dr.
Juergen Drews has informed the Company that he is resigning from the
Board. As previously provided for at the time of the closing of the
merger of GPC Biotech into Agennix AG in November 2009, Dr. von
Bohlen will be filling this seat.

Dr. von Bohlen said: "I am pleased to know that the leadership of
Agennix is in the capable hands of Dr. Hombeck and Dr. Malik, who
have demonstrated their strong management skills over the past year
in advancing the business. I look forward to continuing to serve the
Company as a member of the Supervisory Board."

The Company also reported that, effective February 14, 2011, Alan
Feinsilver filled the Supervisory Board seat opened by the
resignation of Dr. Robert van Leen, which was announced in November
2010. Mr. Feinsilver had previously been named as a replacement
member for Dr. van Leen at the time of the closing of the merger. Mr.
Feinsilver is the owner and President of The Overbrook Company, a
private investment company. He is also the Managing Director of
Centerline Manufacturing Ltd., a private company which produces
specialty parts for the energy industry. He has served on the Board
of Directors of several U.S. firms, including as Chairman of the
Audit Committee for two publicly listed companies. Mr. Feinsilver is
a Certified Public Accountant and an attorney. He holds a Bachelors
degree in Business Administration from the University of Texas and a
Juris doctor degree from the University of Texas School of Law.

"I would like to sincerely thank Dr. Drews and Dr. van Leen for their
service and greatly appreciate their counsel," said Dr. Christof
Hettich, Chairman of the Supervisory Board. "I am very pleased to
welcome Mr. Feinsilver, as well as my colleague, Dr. von Bohlen, to
the Board. Mr. Feinsilver has extensive business experience in both
public and private firms, including financial expertise that will be
invaluable to the Company and Board."

About Agennix Agennix AG is a publicly listed biopharmaceutical
company that is focused on the development of novel therapies that
have the potential to substantially improve the length and quality of
life of critically ill patients in areas of major unmet medical need.
The Company´s most advanced program is talactoferrin, an oral therapy
that has demonstrated activity in randomized, double-blind,
placebo-controlled Phase II studies in non-small cell lung cancer, as
well as in severe sepsis. Talactoferrin is currently in Phase III
clinical trials in non-small cell lung cancer, and Agennix plans to
develop this program further for the treatment of severe sepsis.
Other clinical development programs include RGB-286638, a
multi-targeted kinase inhibitor in Phase I testing, and a topical gel
form of talactoferrin for diabetic foot ulcers. Agennix´s registered
seat is in Heidelberg, Germany. The Company has three sites of
operation: Planegg/Munich, Germany; Princeton, New Jersey and
Houston, Texas. For additional information, please visit the Agennix
Web site at www.agennix.com.

This press release contains forward-looking statements, which express
the current beliefs and expectations of the management of Agennix AG.
Such statements are based on current expectations and are subject to
risks and uncertainties, many of which are beyond our control, that
could cause future results, performance or achievements to differ
significantly from the results, performance or achievements expressed
or implied by such forward-looking statements. Actual results could
differ materially depending on a number of factors, and we caution
investors not to place undue reliance on the forward-looking
statements contained in this press release. Forward-looking
statements speak only as of the date on which they are made and
Agennix undertakes no obligation to update these forward-looking
statements, even if new information becomes available in the future.

Agennix™ is a trademark of the Agennix group.

end of announcement euro adhoc
--------------------------------------------------------------------------------

ots Originaltext: AGENNIX AG
Im Internet recherchierbar: http://www.presseportal.de

Further inquiry note:

Barbara Müller
Manager, Investor Relations & Corporate Communications
Phone: +49 (0)89 8565 2693
ir@agennix.com

In the U.S.: Laurie Doyle
Senior Director, Investor Relations & Corporate Communications
Phone: +1 609 524 5884
laurie.doyle@agennix.com

Additional media contact for Europe:
MC Services AG
Raimund Gabriel
Phone: +49 (0) 89 210 228 0
raimund.gabriel@mc-services.eu

Additional investor contact for Europe:
Trout International LLC
Lauren Williams, Vice President
Phone: +44 207 936 9325
lwilliams@troutgroup.com

Branche: Pharmaceuticals
ISIN: DE000A1A6XX4
WKN: A1A6XX
Index: CDAX, Prime All Share, Technology All Share
Börsen: Frankfurt / regulated dealing/prime standard
Berlin / free trade
Hamburg / free trade
Düsseldorf / free trade
Hannover / free trade
München / free trade